Overview

Busulfan and Cyclophosphamide Followed By ALLO BMT

Status:
Terminated
Trial end date:
2020-02-10
Target enrollment:
Participant gender:
Summary
This is a treatment guideline to allow routine clinical data to be collected and maintained in Oncore (clinical database) and the University of Minnesota Blood and Marrow Database as part of the historical database maintained by the department.
Phase:
N/A
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Allopurinol
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Cyclosporine
Cyclosporins
Etiracetam
Lenograstim
Levetiracetam
Mycophenolate mofetil
Mycophenolic Acid
Sargramostim
Tacrolimus